Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement

By sjmartinez • May 4, 2025

Leboulleux S, Boucai L, Busaidy N, Durante C, Fagin JA, Fazeli S, Gianoukakis AG, Haugen BR, Kang H, Konda B, Laetsch TW, Locati L, Ryder M, Spitzweg C, Worden FP, Wirth L, Ho A. Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement. Lancet Diabetes Endocrinol. 2025 Apr 30:S2213-8587(25)00064-6. doi: 10.1016/S2213-8587(25)00064-6. Epub ahead of print. PMID: 40318680.

Tags: Endocrinology, Harbor UCLA, Publications

Regular Insulin Versus NPH Insulin for Continuous Enteral Tube Feeding in Hospitalized Patients

Kalangi ST, Bokka SM, Anand S, Garg R. Regular Insulin Versus NPH Insulin for Continuous Enteral Tube Feeding in Hospitalized Patients. Clin Diabetes. 2025 Apr[...]

Real-World Interventions for Type 2 Diabetes Prevention (REALITY): A Multisite Study to Assess the Effectiveness and Cost-Effectiveness of the National Diabetes Prevention Program

Herman WH, Tyndall BD, Duru OK, Moin T, McEwen LN, Shao H, Ackermann RT, Jacobs SR, Neuwahl S, Kuo S, Zhang P, Pavkov ME, Villatoro[...]

Nardilysin in adipocyte regulates insulin sensitivity via HIF1alpha and PPARgamma

Matsuda S, Ohno M, Nishi K, Ikeda S, Iwasaki H, Eifuku T, Hiraoka Y, Kimura T, Ono K, Nishi E. Nardilysin in adipocyte regulates insulin[...]